Prof. Markus Graefen
(28 June 2017)
The available biomarkers are not used as good as they could be. PSA density, velocity, free PSA, and a combination of these could be used more. On top of that, there are also predictive tools, such as the PCPT predictive tool and a variety of blood and urinary biomarkers. When looking at all the biomarkers, SelectMDx is a very good one [because of the low risk (2%) of missing clinically significant cancer].